

3rd Business Best Practices Awards**Oryzon received Best Business Practices Award for Innovation**

- This recognition is awarded by El Confidencial in collaboration with KPMG

BARCELONA, SPAIN and CAMBRIDGE, MA, February 3, 2017 – Oryzon Genomics (ISIN Code: ES0167733015, ORY), a public clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, has received the award in the III Edition of the Best Business Practices Awards in the category of Innovation.

Oryzon's Chief Financial Officer and Chief Operating Officer, Enric Rello, received the award from Nacho Cardero, Director of El Confidencial, at the ceremony held yesterday in Madrid. Economy Secretary of State Irene Garrido inaugurated the ceremony and, together with the President of KPMG Spain, Hilario Albarracin, and the Director of El Confidencial, Nacho Cardero, presented the awards.

The award recognizes Oryzon as an innovative company for its continuous pursuit of business excellence over the last 16 years. The Best Business Practices Awards take into consideration companies' business growth and social projection, acknowledging the companies which have a high commitment to diversity, and have implemented innovative initiatives to promote equal and non-discriminatory opportunities in the workplace.

In words of Enric Rello, "it is a great satisfaction for Oryzon's team to receive the Best Business Practices Awards. This is a recognition to the dedication and team effort made over the past 16 years, during which Oryzon has strived to achieve excellence in business practices".

Oryzon has a highly competitive and productive Epigenetics Platform, centered around the development of LSD1 inhibitors, with a first forerunner program licensed to Roche (ORY-1001/RG6016) that has recently finished Phase I/IIA in acute leukemia and is currently being explored in an ongoing Phase I clinical trial in Small Cell Lung Cancer that validates the platform scientifically and clinically. This Platform has so far produced two additional programs: ORY-2001, already in clinical development with multiple indication opportunities that is pioneering the histone demethylases field in neurodegenerative disorders; and ORY-3001, also against LSD1, currently in preclinical development for a yet undisclosed non-oncological orphan indication.

About Oryzon

Founded in 2000 in Barcelona, Spain, Oryzon (ISIN Code: ES0167733015) is a clinical stage biopharmaceutical company considered as the European champion in Epigenetics. The company has one of the strongest portfolios in the field and a clinical asset already partnered with Roche. Oryzon's LSD1 program is currently covered by + 20 patent families and has rendered two compounds in clinical trials. In addition, Oryzon has ongoing programs for developing inhibitors against other epigenetic targets. The

company has a strong technological platform for biomarker identification and performs biomarker and target validation for a variety of malignant and neurodegenerative diseases. Oryzon's strategy is to develop first in class compounds against novel epigenetic targets through Phase II clinical trials, at which point it is decided on a case-by-case basis to either keep the development in-house or to partner or outlicense the compound for late stage development and commercialization. The company has offices in Barcelona and Cambridge, Massachusetts. For more information, visit www.oryzon.com.

FORWARD-LOOKING STATEMENTS

This communication contains forward-looking information and statements about Oryzon Genomics, S.A., including financial projections and estimates and their underlying assumptions, statements regarding plans, objectives and expectations with respect to future operations, capital expenditures, synergies, products and services, and statements regarding future performance. Forward-looking statements are statements that are not historical facts and are generally identified by the words "expects", "anticipates", "believes", "intends", "estimates" and similar expressions. Although Oryzon Genomics, S.A. believes that the expectations reflected in such forward-looking statements are reasonable, investors and holders of Oryzon Genomics, S.A. shares are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Oryzon Genomics, S.A., that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include those discussed or identified in the documents sent by Oryzon Genomics, S.A. to the *Comisión Nacional del Mercado de Valores*, which are accessible to the public. Forward-looking statements are not guarantees of future performance. The auditors of Oryzon Genomics, S.A. have not reviewed them. You are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date they were made. All subsequent oral or written forward-looking statements attributable to Oryzon Genomics, S.A. or any of its members, directors, officers, employees or any persons acting on its behalf are expressly qualified in their entirety by the cautionary statement above. All forward-looking statements included herein are based on information available to Oryzon Genomics, S.A. on the date hereof. Except as required by applicable law, Oryzon Genomics, S.A. does not undertake any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. This press release is not an offer of securities for sale in the United States. The Company's securities may not be offered or sold in the United States absent registration or an exemption from registration. Any public offering of the Company's securities to be made in the United States will be made by means of a prospectus that may be obtained from the Company or the selling security holder, as applicable, that will contain detailed information about the Company and management, as well as financial statements.

US Contact:
The Trout Group
Maria Kelman
+1 646 378 2932
mkelman@troutgroup.com

Spain:
ATREVIA
Patricia Cobo/Luis Rejano
+34 91 564 07 25
pcobo@atrevia.com
lrejano@atrevia.com

The Company:
Anna K Baran
IR Director
+44 (0) 752 1083 006
abaran@oryzon.com